National Comprehensive Cancer Network

Acute Lymphoblastic Leukemia Panel

• Ponatinib - Submitted by Ariad Pharmaceuticals on 12/21/2012
• Erwinia Asparaginase - Submitted by SMT, Inc. on 04/05/2013
• Glucarpidase - Submitted by BTG International on 05/03/2013
• Ponatinib - Submitted by Ariad Pharmaceuticals on 01/15/2014
• ClonoSIGHT™ MRD test - Submitted by Sequenta, Inc. on 10/15/2014
• Blinatumomab - Submitted by Amgen, Inc. on 10/03/2016
• Multiplex PCR and high throughput sequencing (HTS) platform - Submitted by Adaptive Biotechnologies on 12/09/2016
• Ponatinib - Submitted by ARIAD Pharmaceuticals Inc on 12/19/2016
• Blinatumomab - Submitted by Amgen, Inc. on 03/20/2017

Acute Myeloid Leukemia Panel

• Sorafenib - Submitted by Onyx Pharmaceuticals on 04/08/2014
• Isocitrate dehydrogenase (IDH) testing - Submitted by Celgene Corporation on 07/14/2016
• Midostaurin - Submitted by Novartis Pharmaceuticals Corporation on 05/02/2017

Adult Cancer Pain Panel

• Magnetic resonance-guided focused ultrasound - Submitted by Insightec on 09/12/2016

Antiemesis Panel

• Granisetron Transdermal System - Submitted by ProStrakan on 09/25/2014
• Aprepitant - Submitted by Merck & Co., Inc. on 09/10/2015
• Granisetron Injection - Submitted by Heron Therapeutics, Inc. on 09/15/2015
• Rolapitant - Submitted by TESARO, Inc. on 09/21/2015
• Fosaprepitant Dimeglumine - Submitted by Merck & Co., Inc. on 10/22/2015
• Fosaprepitant Dimeglumine - Submitted by Merck & Co., Inc. on 02/12/2016
• Rolapitant - Submitted by Tesaro, Inc. on 06/17/2016
• Granisetron - Submitted by Heron Therapeutics, Inc. on 08/10/2016
• Fosaprepitant Dimeglumine - Submitted by Merck & Co., Inc. on 10/17/2016

Bladder/Penile Cancers Panel

• Albumin-bound paclitaxel - Submitted by Celgene on 03/07/2014
• Eribulin Mesylate - Submitted by Eisai, Inc. on 07/07/2015
• Radiation Therapy - Submitted by American Society for Radiation Oncology on 09/10/2015
• Radiation Therapy - Submitted by American Society for Radiation Oncology on 09/10/2015
• Atezolizumab - Submitted by Genentech, Inc. on 05/18/2016
• Nivolumab - Submitted by Bristol-Myers Squibb Company on 06/06/2016
• Atezolizumab - Submitted by Genentech, Inc. on 08/21/2016
• Nivolumab - Submitted by Bristol-Myers Squibb Company on 10/10/2016
• Nivolumab - Submitted by Bristol-Myers Squibb Company on 02/03/2017
• Pembrolizumab - Submitted by Merck & Co., Inc. on 02/20/2017
• Atezolizumab - Submitted by Genentech, Inc. on 04/17/2017
• Durvalumab - Submitted by AstraZeneca on 05/02/2017
• Avelumab - Submitted by EMD Serono, Inc. on 05/09/2017
• Pembrolizumab - Submitted by Merck & Co., Inc. on 05/19/2017

Breast Cancer Panel

• Bevacizumab - Submitted by Genentech on 06/25/2010
• Eribulin - Submitted by Eisai on 11/17/2010
• Denosumab - Submitted by Amgen on 12/21/2010
• Zoledronic Acid - Submitted by Novartis Pharmaceuticals Corporation on 05/09/2011
• Everolimus - Submitted by Novartis Pharmaceuticals Corporation on 10/10/2011
• Pertuzumab - Submitted by Genentech on 06/01/2012
• Ado-Trastuzumab Emtansine - Submitted by Genentech on 02/22/2013
• Toremifene Citrate - Submitted by ProStrakan, Inc on 05/17/2013
• Everolimus - Submitted by Novartis on 06/26/2013
• Breast-Specific Gamma Imaging (BSGI) - Submitted by Dilon Technologies on 06/27/2013
• Pertuzumab - Submitted by Genentech on 07/01/2013
• Pertuzumab - Submitted by Genentech on 10/01/2013
• Fluoropyrimidine - Submitted by Ken Surprenant on 04/06/2014
• Everolimus - Submitted by Novartis on 04/23/2014
• Breast Cancer Index (BCI) - Submitted by bioTheranostics on 06/10/2014
• Toremifene - Submitted by ProStrakan on 06/17/2014
• Toremifene - Submitted by ProStrakan on 06/17/2014
• CELLSEARCH Circulating Tumor Cell Test - Submitted by Janssen Diagnostics on 06/20/2014
• Prosigna Breast Cancer Gene Signature Assay - Submitted by Nanostring Technologies on 06/20/2014
• L-Dex U400 - Submitted by ImpediMed, Inc on 06/23/2014
• HERmark - Submitted by LabCorp on 06/27/2014
• Oncotype DX Breast Cancer Assay - Submitted by Genomic Health on 06/27/2014
• HER-2 Blood Test - Submitted by Nuclea Diagnostic Laboratories on 06/27/2014
• Everolimus - Submitted by Novartis on 06/30/2014
• Tamoxifen - Submitted by DARA BioSciences, Inc. on 06/30/2014
• Ado-Trastuzumab Emtansine - Submitted by Genentech on 08/08/2014
• Pertuzumab/Trastuzumab - Submitted by Genentech on 11/06/2014
• Everolimus - Submitted by Novartis on 12/18/2014
• Palbociclib - Submitted by Pfizer Inc. on 06/02/2015
• Breast Cancer Index (BCI) - Submitted by bioTheranostics, Inc. on 06/12/2015
• Prosigna® Breast Cancer Gene Signature Assay - Submitted by NanoString Technologies on 06/19/2015
• Pertuzumab/Trastuzumab - Submitted by Genentech on 06/29/2015
• Denosumab - Submitted by Amgen on 07/13/2015
• Zoledronic Acid - Submitted by Sylvester Comprehensive Cancer Center/University of Miami Hospital and Clinics on 01/15/2016
• Denosumab - Submitted by Amgen, Inc. on 03/25/2016
• Palbociclib - Submitted by Pfizer Inc. Oncology on 04/26/2016
• Albumin-bound paclitaxel - Submitted by Celgene Corporation on 04/28/2016
• Preoperative HER2-targeted therapy - Submitted by Genentech, Inc. on 05/09/2016
• Pembrolizumab - Submitted by Merck & Co., Inc. on 05/13/2016
• Albumin-bound paclitaxel - Submitted by Celgene Corporation on 06/07/2016
• Breast Cancer Index (BCI) test - Submitted by Biotheranostics, Inc. on 06/14/2016
• Prosigna® Breast Cancer Gene Signature Assay - Submitted by NanoString Technologies on 06/14/2016
• Oncotype DX® Invasive Breast Cancer Assay - Submitted by Genomic Health Inc. on 06/17/2016
• Oncotype DX® Breast Cancer Assay - Submitted by Genomic Health Inc. on 06/17/2016
• Biomarker assay - Submitted by Myriad Genetic Laboratories, Inc. on 06/20/2016
• Everolimus - Submitted by Novartis Pharmaceuticals Corporation on 06/20/2016
• Ribociclib - Submitted by Novartis Pharmaceuticals Corporation on 03/13/2017

Breast Cancer Screening and Diagnosis Panel

• Breast-Specific Gamma Imaging (BSGI) - Submitted by Mandell and Blau MD’s PC/Legacy Medical Group-Surgical Oncology on 12/17/2014
• Digital Breast Tomosynthesis - Submitted by Hologic, Inc. on 12/18/2015
• Digital Breast Tomosynthesis - Submitted by University of Pennsylvania School of Medicine on 01/14/2016
• Breast Cancer Family Histories - Submitted by Myriad Genetic Laboratories, Inc. on 02/05/2016

Cancer- and Chemotherapy-Induced Anemia Panel

• ESA REMS and ESA APPRISE Oncology Programs - Submitted by Amgen, Inc. on 04/14/2017

Cancer-Associated Venous Thromboembolic Disease Panel

• Tinzaparin - Submitted by LEO Pharma on 10/20/2014

Central Nervous System Cancers Panel

• Sunitinib - Submitted by Pfizer Inc, Pfizer Oncology on 08/20/2014
• NovoTTF^TM-100A System - Submitted by Musella Foundation For Brain Tumor Research & Information, Inc on 10/01/2014
• NovoTTF^TM-100A System - Submitted by Novocure Inc. on 10/01/2014
• NovoTTF^TM-100A System - Submitted by Accelerate Brain Cancer Cure on 11/24/2014
• NovoTTF^TM-100A System - Submitted by Musella Foundation For Brain Tumor Research & Information, Inc on 11/24/2014
• NovoTTF^TM-100A System - Submitted by National Brain Tumor Society on 11/25/2014
• CNS brain metastatic lesions - Submitted by Jiang Aijun and Zheng Xia on 08/23/2015
• Tumor treating fields (TTFields) - Submitted by Novocure Inc. on 11/06/2015
• Radiation therapy recommendations - Submitted by The American Society for Radiation Oncology (ASTRO) on 12/02/2015
• TTFields update - Submitted by Novocure Inc. on 12/15/2015

Cervical/Uterine Cancers Panel

• Tamoxifen - Submitted by Sarcoma Unit Royal Marsden Hospital, United Kingdom on 08/15/2012
• Bevacizumab - Submitted by Genentech on 02/20/2014
• Trabectedin - Submitted by Janssen Biotech, Inc. on 10/23/2015
• Mutation prediction models (ie MMRpro, PREMM [1,2,6] or MMRpredict) - Submitted by Myriad Genetic Laboratories, Inc. on 05/02/2016

Chronic Myeloid Leukemia Panel

• Nilotinib - Submitted by Novartis Pharmaceuticals Corporation on 06/07/2010
• Bosutinib - Submitted by Pfizer Oncology on 09/04/2012
• Ponatinib - Submitted by Ariad Pharmaceuticals on 12/21/2012
• Ponatinib - Submitted by Ariad Pharmaceuticals on 01/09/2014
• Ponatinib - Submitted by Ariad Pharmaceuticals on 05/16/2014
• Nilotinib - Submitted by Novartis Pharmaceuticals Corporation on 06/17/2016

Colon/Rectal/Anal Cancers Panel

• Bevacizumab - Submitted by Genentech on 06/08/2010
• Cetuximab - Submitted by Bristol-Myers Squibb on 05/16/2011
• Capecitabine (Colon Cancer) - Submitted by Genentech on 06/07/2011
• Capecitabine (Rectal Cancer) - Submitted by Genentech on 06/07/2011
• Bevacizumab - Submitted by Genentech on 06/05/2012
• Ziv-aflibercept - Submitted by Sanofi on 08/03/2012
• Regorafenib - Submitted by Bayer HealthCare on 10/03/2012
• Fluoropyrimidine Pre-Screening - Submitted by Ken Surprenant on 03/23/2014
• Oncotype DX® Colon Cancer Assay - Submitted by Genomic Health on 05/16/2014
• PET/CT - Submitted by Medical Imaging & Technology Alliance on 05/28/2014
• PET/CT - Submitted by Medical Imaging & Technology Alliance on 05/28/2014
• Bevacizumab - Submitted by Genentech on 06/02/2014
• Mitomycin C - Submitted by Personalized Cancer Medicine on 02/23/2015
• Fluoropyrimidine - Submitted by Ken Surprenant on 04/05/2015
• Ramucirumab - Submitted by Lilly Oncology on 04/28/2015
• Ziv-Aflibercept - Submitted by Sanofi on 08/18/2015
• Regorafenib - Submitted by Bayer HealthCare on 08/19/2015
• Trifluridine and Tipiracil - Submitted by Taiho Oncology on 09/22/2015
• Pembrolizumab - Submitted by Merck & Co., Inc. on 02/01/2016
• Uridine Triacetate - Submitted by Wellstat Therapeutics Corporation on 07/01/2016
• Yttrium-90 resin microspheres - Submitted by Sirtex Medical Inc. on 07/15/2016
• Cytoreductive surgery and intraperitoneal chemotherapy - Submitted by Kiran K. Turaga MD MPH, H. Richard Alexander MD PhD, and David Bartlett MD on 07/20/2016
• EGFR tumor location - Submitted by Amgen, Inc. on 12/19/2016
• Panitumumab - Submitted by Amgen, Inc. on 01/30/2017
• Vemurafenib - Submitted by Genentech, Inc. on 02/22/2017

Distress Management Panel

• PHQ-2 and PHQ-9 Questionnaire - Submitted by Wake Forest School of Medicine on 12/21/2016

Esophageal/Gastric Cancers Panel

• Capecitabine - Submitted by Genentech on 08/17/2011
• Albumin-bound paclitaxel - Submitted by Celgene on 10/02/2013
• Nivolumab or nivolumab in combination with ipilimumab - Submitted by Bristol-Myers Squibb on 06/04/2016
• Uridine triacetate - Submitted by Wellstat Therapeutics Corporation on 08/17/2016

Genetic/Familial High-Risk Assessment: Breast and Ovarian Panel

• Familial Risk Management - Submitted by Myriad on 10/19/2015
• Multi-Gene Panel - Submitted by Myriad on 10/19/2015
• Multigene Panel Testing - Submitted by Myriad Genetic Laboratories, Inc. on 05/14/2016
• Personal History of Pancreatic Cancer - Submitted by Myriad Genetic Laboratories, Inc. on 05/14/2016

Genetic: Colorectal/Colorectal Cancer Screening Panel

• Multi-syndrome gene panel - Submitted by Myriad on 10/08/2015
• Cologuard - Submitted by Exact Sciences Inc. on 05/27/2016
• Genetic risk assessment - Submitted by Myriad Genetic Laboratories, Inc. on 11/10/2016
• LS-specific testing - Submitted by Myriad Genetic Laboratories, Inc. on 11/10/2016
• Multi-gene testing - Submitted by Myriad Genetic Laboratories, Inc. on 11/10/2016

Head and Neck Cancers Panel

• Fluoropyrimidine Pre-Screening - Submitted by Ken Surprenant on 04/06/2014
• Afatinib - Submitted by Boehringer-Ingelheim Pharmaceuticals, Inc on 06/10/2015
• Nivolumab - Submitted by Bristol Myers Squibb Company on 04/19/2016
• Nivolumab - Submitted by Bristol Myers Squibb Company on 06/06/2016
• Pembrolizumab - Submitted by Merck & Co., Inc. on 06/15/2016
• Principles of Nutrition - Submitted by Oncology Nutrition Dietetic Practice Group, Academy of Nutrition and Dietetics on 07/06/2016
• Technetium Tc 99m tilmanocept - Submitted by Navidea Biopharmaceuticals on 07/18/2016
• Pembrolizumab - Submitted by Merck & Co., Inc. on 08/05/2016
• Pembrolizumab - Submitted by Merck & Co., Inc. on 09/19/2016

Hepatobiliary Cancers Panel

• Regorafenib - Submitted by Bayer HealthCare on 06/30/2016
• Nivolumab - Submitted by Bristol-Myers Squibb Company on 09/26/2016

Hodgkin Lymphoma Panel

• Brentuximab - Submitted by Seattle Genetics on 08/22/2011
• Brentuximab vedotin - Submitted by Seattle Genetics on 09/05/2014
• Brentuximab vedotin - Submitted by Seattle Genetics on 09/05/2014
• Panobinostat - Submitted by Novartis Pharmaceuticals Organization on 02/24/2015
• Nivolumab - Submitted by Bristol-Myers Squibb Company on 06/25/2015
• Nivolumab - Submitted by Bristol-Myers Squibb on 05/18/2016
• Nivolumab - Submitted by Bristol-Myers Squibb on 07/21/2016

Kidney Cancer Panel

• Cabozantinib - Submitted by Exelixis, Inc. on 06/06/2016

Kidney/Testicular Cancers Panel

• Denosumab - Submitted by Amgen on 07/18/2011
• Axitinib - Submitted by Pfizer Oncology on 01/31/2012
• Everolimus - Submitted by Novartis Pharmaceutical Corporation on 12/13/2012
• Axitinib - Submitted by Pfizer on 02/24/2014
• Lenvatinib - Submitted by Eisai Inc. on 09/08/2015
• Cabozantinib - Submitted by Exelixis, Inc. on 09/26/2015
• Nivolumab - Submitted by Bristol-Myers Squibb on 09/28/2015
• Nivolumab - Submitted by Bristol-Myers Squibb on 11/23/2015
• Lenvatinib - Submitted by Eisai, Inc. on 05/26/2016

Lung Cancer Screening Panel

• Tomosynthesis - Submitted by General Electric Healthcare on 03/07/2014

Melanoma Panel

• Ipilimumab - Submitted by Bristol-Myers Squibb on 03/25/2011
• Vemurafenib - Submitted by Genentech on 08/22/2011
• Albumin-bound paclitaxel - Submitted by Celgene on 12/21/2012
• Pembrolizumab - Submitted by Merck & Co, Inc on 09/08/2014
• Pembrolizumab - Submitted by Merck & Co, Inc on 09/08/2014
• Nivolumab - Submitted by Bristol-Myers Squibb Company on 12/22/2014
• Ipilimumab - Submitted by Bristol-Myers Squibb Company on 04/15/2015
• Pembrolizumab - Submitted by Merck & Co., Inc. on 05/05/2015
• Comprehensive genomic profiling (CGP) - Submitted by Foundation Medicine, Inc. on 05/20/2015
• Nivolumab/Ipilimumab - Submitted by Bristol-Myers Squibb Company on 10/01/2015
• Talimogene laherparepvec - Submitted by Amgen Inc. on 10/28/2015
• Ipilimumab - Submitted by Bristol-Myers Squibb Company on 10/29/2015
• Cobimetinib/vemurafenib - Submitted by Genentech, Inc. on 11/10/2015
• Cobimetinib - Submitted by Genentech, Inc. on 11/24/2015
• Nivolumab - Submitted by Bristol-Myers Squibb Company on 11/30/2015
• Pembrolizumab - Submitted by Merck & Co., Inc on 03/09/2016
• Pembrolizumab - Submitted by Merck & Co., Inc on 06/19/2016
• Decision Dx-Melanoma test - Submitted by Castle Biosciences, Inc. on 06/24/2016
• Counseling and genetic testing - Submitted by Oregon Health and Science University on 06/27/2016
• Genetic risk assessment/testing - Submitted by Myriad Genetic Laboratories, Inc. on 06/29/2016
• Ipilimumab - Submitted by Bristol-Myers Squibb Company on 10/09/2016

Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström's Macroglobulinemia Panel

• Zoledronic Acid - Submitted by Novarits on 03/09/2011
• Bortezomib - Submitted by Millennium on 03/25/2011
• Bortezomib - Submitted by Millennium on 03/25/2011
• Vorinostat - Submitted by Merck on 02/24/2012
• Bortezomib - Submitted by Millennium on 04/10/2012
• Bortezomib - Submitted by Millennium on 04/10/2012
• Lenalidomide - Submitted by Celgene on 05/17/2012
• Carfilzomib - Submitted by Onyx on 07/30/2012
• Carfilzomib - Submitted by Onyx on 01/17/2013
• Pomalidomide - Submitted by Celgene on 02/11/2013
• Bortezomib - Submitted by Millennium on 03/28/2013
• Bortezomib - Submitted by Millennium on 03/28/2013
• Bortezomib - Submitted by Millennium on 03/28/2013
• Carfilzomib - Submitted by Onyx on 04/19/2013
• Lenalidomide - Submitted by Celgene on 07/31/2013
• Ibrutinib - Submitted by Janssen Biotech on 11/13/2013
• Pomalidomide - Submitted by Celgene on 10/09/2014
• Panobinostat - Submitted by Novartis on 08/12/2015
• Daratumumab - Submitted by Janssen Biotech, Inc. on 11/23/2015
• Elotuzumab - Submitted by Bristol-Myers Squibb Company on 11/30/2015
• Ixazomib - Submitted by Takeda on 12/01/2015
• Ixazomib - Submitted by Takeda on 12/01/2015
• Ixazomib - Submitted by Takeda on 12/11/2015
• Carfilzomib - Submitted by Amgen Inc. on 02/11/2016
• Carfilzomib - Submitted by Amgen Inc. on 02/11/2016
• Bendamustine Hydrochloride - Submitted by Teva Pharmaceuticals, Inc. on 03/23/2016
• Pomalidomide - Submitted by Celgene Corporation on 04/08/2016
• Lenalidomide - Submitted by Celgene Corporation on 04/08/2016
• Lenalidomide - Submitted by Celgene Corporation on 04/08/2016
• Pomalidomide - Submitted by Celgene Corporation on 04/08/2016
• Pomalidomide - Submitted by Celgene Corporation on 04/08/2016
• Pomalidomide - Submitted by Celgene Corporation on 04/08/2016
• Pomalidomide - Submitted by Celgene Corporation on 04/08/2016
• Pomalidomide - Submitted by Celgene Corporation on 04/08/2016
• Pomalidomide - Submitted by Celgene Corporation on 04/08/2016
• Panobinostat - Submitted by Novartis Pharmaceuticals Corporation on 04/11/2016
• Carfilzomib - Submitted by The University of Chicago, Department of Medicine on 04/11/2016
• Elotuzumab - Submitted by Bristol-Myers Squibb Company on 04/21/2016
• MyPRS - Submitted by Signal Genetics, Inc. on 05/02/2016
• MyPRS - Submitted by Signal Genetics, Inc. on 05/02/2016
• MyPRS - Submitted by Signal Genetics, Inc. on 05/02/2016
• Daratumumab - Submitted by Janssen Biotech, Inc. on 06/07/2016
• Lenalidomide - Submitted by Celgene Corporation on 06/20/2016
• Pomalidomide - Submitted by Celgene Corporation on 06/29/2016
• Carfilzomib - Submitted by Amgen Inc. on 07/27/2016
• Carfilzomib - Submitted by Amgen Inc. on 07/27/2016
• Lenalidomide - Submitted by Celgene Corporation on 08/25/2016
• Carfilzomib - Submitted by Amgen Inc. on 10/07/2016
• Lenalidomide - Submitted by Celgene Corporation on 10/20/2016
• Daratumumab - Submitted by Janssen Biotech, Inc. on 10/21/2016

Myelodysplastic Syndromes Panel

• Lenalidomide - Submitted by Celgene on 12/22/2014
• Lenalidomide - Submitted by Celgene on 07/11/2016

Myeloid Growth Factors Panel

• Filgrastim-sndz - Submitted by Sandoz Inc. on 02/04/2015
• Pegfilrastim delivery kit/on-body injector - Submitted by Amgen, Inc. on 05/13/2015
• Regimens with a high/intermediate risk for febrile neutropenia - Submitted by Hospital Universitario de Getafe on 10/20/2015
• Plerixafor dosing and references - Submitted by Sanofi U.S. on 12/14/2015

Neuroendocrine Tumors Panel

• Sunitinib - Submitted by Pfizer Oncology on 08/18/2009
• Everolimus - Submitted by Novartis Pharmaceuticals Corporation on 09/08/2010
• Sunitinib - Submitted by Pfizer Oncology on 02/25/2011
• Lanreotide - Submitted by Ipsen Biopharmaceuticals, Inc. on 11/14/2012
• Lanreotide - Submitted by Ipsen Biopharmaceuticals, Inc. on 06/23/2014
• Everolimus - Submitted by Novartis Oncology on 10/20/2015
• Everolimus - Submitted by Novartis Oncology on 03/18/2016
• Gallium-68 Dotatate PET/CT - Submitted by Medical Imaging and Technology Alliance on 06/15/2016
• Telotristat ethyl - Submitted by Lexicon Pharmaceuticals, Inc. on 03/09/2017

Non-Hodgkin`s Lymphomas Panel

• Fludarabine - Submitted by sanofi-aventis on 04/05/2010
• Alemtuzumab - Submitted by Genzyme on 05/10/2010
• Ibritumomab - Submitted by Spectrum Pharmaceuticals, Inc. on 05/12/2010
• Bortezomib - Submitted by Millennium on 05/25/2010
• Rasburicase - Submitted by sanofi-aventis on 05/25/2010
• Pralatrexate - Submitted by Allos Therapeutics on 06/02/2010
• Rituximab - Submitted by Genentech on 06/08/2010
• Rituximab - Submitted by Genentech on 01/11/2011
• Bortezomib - Submitted by Millennium on 04/08/2011
• Rituximab - Submitted by Genentech on 06/21/2011
• Rituximab - Submitted by Genentech on 06/22/2011
• Rituximab - Submitted by Genentech on 06/22/2011
• Rituximab - Submitted by Genentech on 06/22/2011
• Brentuximab Vedotin - Submitted by Seattle Genetics on 08/19/2011
• Rituximab - Submitted by Genentech on 12/22/2011
• Rituximab - Submitted by Genentech on 02/29/2012
• Glucarpidase - Submitted by BTG International on 04/26/2012
• Lenalidomide - Submitted by Celgene on 06/05/2012
• Rituximab - Submitted by Genentech on 06/12/2012
• Rituximab - Submitted by Genentech on 05/07/2013
• Brentuximab vedotin - Submitted by Seattle Genetics on 06/20/2013
• Lenalidomide - Submitted by Celgene on 06/27/2013
• Lenalidomide - Submitted by Celgene on 06/27/2013
• Obinutuzumab - Submitted by Genentech on 11/01/2013
• Ibrutinib - Submitted by Janssen Biotech on 11/13/2013
• Ibrutinib - Submitted by Janssen Biotech on 11/13/2013
• Ibrutinib - Submitted by Janssen Biotech on 11/13/2013
• Ibrutinib - Submitted by Janssen Biotech on 11/13/2013
• Panobinostat - Submitted by Novartis on 02/24/2014
• Rituximab - Submitted by Genentech on 04/16/2014
• Brentuximab vedotin (DLBCL) - Submitted by Seattle Genetics on 05/28/2014
• Brentuximab vedotin (CTCL) - Submitted by Seattle Genetics on 05/28/2014
• Bortezomib - Submitted by Millennium on 06/02/2014
• Obinutuzumab - Submitted by Genentech on 06/02/2014
• Ibritumomab tiuxetan - Submitted by Spectrum Pharmaceuticals on 06/02/2014
• Lenalidomide - Submitted by Celgene on 06/02/2014
• Lenalidomide - Submitted by Celgene on 06/03/2014
• Ibrutinib (CLL) - Submitted by Pharmacyclics on 06/11/2014
• Ibrutinib (CLL- elderly) - Submitted by Pharmacyclics on 06/11/2014
• Idelalisib - Submitted by Gilead Sciences on 07/23/2014
• Ibrutinib - Submitted by Pharmacyclics, Inc. on 07/28/2014
• Idelalisib - Submitted by Gilead Sciences on 07/30/2014
• Ofatumumab - Submitted by GlaxoSmithKline on 09/10/2014
• Ibrutinib - Submitted by Pharmacyclics on 01/29/2015
• Obinutuzumab - Submitted by Genentech on 06/03/2015
• Ibrutinib - Submitted by Pharmacyclics on 06/05/2015
• Ibrutinib - Submitted by Pharmacyclics on 12/07/2015
• Ibrutinib - Submitted by Pharmacyclics on 12/07/2015
• Obinutuzumab - Submitted by Genentech on 12/09/2015
• Obinutuzumab - Submitted by Genentech on 12/09/2015
• Obinutuzumab - Submitted by Genentech, Inc. on 02/26/2016
• Venetoclax - Submitted by AbbVie Inc. on 04/12/2016
• Ibrutinib - Submitted by Pharmacyclics on 05/09/2016
• Rasburicase - Submitted by Sanofi U.S. on 05/26/2016
• Brentuximab vedotin - Submitted by Seattle Genetics, Inc. on 05/26/2016
• Ofatumumab - Submitted by Novartis Pharmaceuticals Corporation on 06/03/2016
• Obinituzumab - Submitted by Genentech, Inc. on 12/05/2016
• Ibrutinib + Rituximab - Submitted by Pharmacyclics on 12/07/2016
• Ibrutinib - Submitted by Pharmacyclics on 01/19/2017

Non-Melanoma Skin Cancer Panel

• Vismodegib - Submitted by Genentech on 01/31/2012

Non-Small Cell Lung Cancer/Malignant Pleural Mesothelioma/Thymomas and Thymic Carcinomas Panel

• Erlotinib - Submitted by Genentech on 06/18/2010
• Erlotinib-Bevacizumab - Submitted by Genentech on 06/18/2010
• Erlotinib - Submitted by Genentech on 06/09/2011
• Erlotinib - Submitted by Genentech on 02/21/2012
• Albumin-bound Paclitaxel with Carboplatin - Submitted by Celgene on 06/25/2012
• Erlotinib - Submitted by Genentech on 07/06/2012
• Bevacizumab - Submitted by Oncology Analytics on 12/31/2012
• Afatinib - Submitted by Boehringer Ingelheim on 04/24/2013
• Bevacizumab - Submitted by Genentech on 04/16/2014
• Ceritinib - Submitted by Novartis on 05/01/2014
• FDG PET/CT - Submitted by Medical Imaging & Technology Alliance on 06/01/2014
• Bevacizumab, Erlotinib - Submitted by Genentech on 06/09/2014
• Erlotinib - Submitted by Genentech on 06/13/2014
• VeriStrat® - Submitted by Biodesix on 06/18/2014
• RNA Assay - Submitted by Myriad on 06/25/2014
• Oligometastases, Oligorecurrence, and Oligoprogression - Submitted by Independent Lung Cancer Patient Advocates on 06/25/2014
• Ceritinib - Submitted by Novartis on 06/27/2014
• Bevacizumab, Erlotinib - Submitted by Genentech on 08/28/2014
• Vemurafenib, Dabrafenib, Cabozantinib - Submitted by Oncology Analytics on 10/06/2014
• Ramucirumab - Submitted by Lilly Oncology on 12/22/2014
• Vemurafenib, Dabrafenib, Crizotinib - Submitted by Oncology Analytics on 02/18/2015
• Bevacizumab - Submitted by Genentech on 03/10/2015
• Afatinib with Cetuximab - Submitted by Boehringer Ingelheim on 03/23/2015
• Pembrolizumab - Submitted by Merck on 04/27/2015
• Nivolumab - Submitted by Bristol-Myers Squibb Company on 06/06/2015
• Bevacizumab - Submitted by Genentech on 06/08/2015
• Afatinib - Submitted by Boehringer Ingelheim on 06/10/2015
• Cabozantinib - Submitted by Exelixis on 06/10/2015
• Molecular Testing - Submitted by Myriad on 07/06/2015
• Afatinib - Submitted by Boehringer Ingelheim on 07/07/2015
• Validated Comprehensive Genomic Profiling (VCGP) Assays - Submitted by Foundation Medicine on 07/10/2015
• Gefitinib - Submitted by AstraZeneca on 07/27/2015
• Pembrolizumab - Submitted by Merck on 10/02/2015
• Nivolumab - Submitted by Bristol-Myers Squibb on 10/09/2015
• Necitumumab - Submitted by Eli Lilly and Company on 11/25/2015
• Ramucirumab - Submitted by Eli Lilly and Company on 11/30/2015
• Alectinib - Submitted by Genentech on 12/11/2015
• Pembrolizumab - Submitted by Merck on 12/20/2015
• Bevacizumab - Submitted by Genentech on 01/21/2016
• Necitumumab - Submitted by Eli Lilly and Company on 03/25/2016
• Osimertinib - Submitted by AstraZeneca on 05/13/2016
• Nivolumab, Ipilimumab - Submitted by Bristol-Myers Squibb Company on 06/04/2016
• Alectinib - Submitted by Genentech, Inc. on 06/06/2016
• Molecular Prognostic Score - Submitted by Myriad Genetic Laboratories, Inc. on 06/08/2016
• Atezolizumab - Submitted by Genentech, Inc. on 06/09/2016
• Tyrosine Kinase Inhibitors - Submitted by Boehringer Ingelheim Pharmaceuticals Inc. on 06/15/2016
• Test Results - Submitted by Boehringer Ingelheim Pharmaceuticals Inc. on 06/16/2016
• Ceritinib - Submitted by Novartis Pharmaceuticals Corporation on 06/17/2016
• Osimertinib - Submitted by AstraZeneca on 06/17/2016
• Erlotinib - Submitted by Genentech, Inc. on 06/20/2016
• Necitumumab - Submitted by Upstage Lung Cancer on 06/20/2016
• Nivolumab - Submitted by Bristol-Myers Squibb Company on 06/28/2016
• Pembrolizumab - Submitted by Merck & Co., Inc. on 10/11/2016
• Pembrolizumab - Submitted by Merck & Co., Inc. on 10/12/2016
• Atezolizumab - Submitted by Genentech, Inc. on 10/18/2016
• Ceritinib - Submitted by Novartis Pharmaceuticals Corporation on 12/05/2016
• Atezolizumab - Submitted by Genentech, Inc. on 12/12/2016
• Osimertinib - Submitted by AstraZeneca on 12/14/2016
• Ceritinib - Submitted by Novartis Pharmaceuticals Corporation on 03/08/2017
• Pembrolizumab - Submitted by Merck & Co., Inc. on 04/25/2017
• Brigatinib - Submitted by Takeda Oncology on 05/09/2017
• Alectinib - Submitted by Genentech, Inc. on 06/06/2017
• Nivolumab - Submitted by Bristol-Myers Squibb Company on 06/06/2017

Occult Primary Panel

• Gene Expression Profiling (GEP) - Submitted by bioTheranostics, Inc. on 06/10/2014

Older Adult Oncology Panel

• Bevacizumab - Submitted by Genentech on 03/10/2015

Ovarian Cancer Panel

• Bevacizumab - Submitted by Genentech on 05/11/2010
• Bevacizumab - Submitted by Genentech on 06/10/2011
• Bevacizumab - Submitted by Genentech on 01/25/2012
• Erlotinib - Submitted by Genentech on 06/13/2012
• Bevacizumab - Submitted by Genentech on 06/22/2012
• Doxorubicin - Submitted by Oncology Analytics on 12/13/2012
• Bevacizumab - Submitted by Genentech on 10/11/2013
• Olaparib - Submitted by AstraZeneca on 12/22/2014
• Bevacizumab - Submitted by Genentech on 05/07/2015
• Bevacizumab - Submitted by Genentech on 10/01/2015
• BRCA test - Submitted by Ovarian Cancer National Alliance on 10/15/2015
• Biomarker assays - Submitted by Vermillion Inc. on 10/16/2015
• ChemoFx® assay - Submitted by Helomics on 10/21/2015
• Genetic testing for BRCA status - Submitted by Myriad Genetics Laboratories, Inc. on 10/23/2015
• Olaparib - Submitted by AztraZeneca on 09/13/2016
• Trabectedin/docetaxel - Submitted by Janssen Biotech on 09/30/2016
• Multivariate index assay test OVA1 - Submitted by Vermillion/ASPiRA Labs on 10/18/2016
• Bevacizumab - Submitted by Genentech on 12/07/2016
• Rucaparib - Submitted by Clovis Oncology on 12/20/2016
• Niraparib - Submitted by Tesaro on 04/11/2017

Pancreatic Adenocarcinoma Panel

• Paclitaxel - Submitted by Abraxis on 02/09/2010
• Docetaxel - Submitted by sanofi-aventis on 07/12/2010
• Oxaliplatin - Submitted by sanofi-aventis on 07/12/2010
• Albumin-bound paclitaxel - Submitted by Celgene Corporation on 08/21/2015
• Familial/genetic risk assessment - Submitted by Myriad Genetics Laboratories, Inc. on 08/21/2015
• Irinotecan liposome injection - Submitted by Merrimack Pharmaceuticals on 04/11/2016
• Irreversible electroporation - Submitted by AngioDynamics on 08/10/2016
• Genetic testing - Submitted by Myriad Genetic Laboratories, Inc. on 08/11/2016

Prevention and Treatment of Cancer-Related Infections Panel

• Fidaxomicin - Submitted by Cubist Pharmaceuticals on 09/11/2014
• Isavuconazonium sulfate - Submitted by Astellas Pharma Global Development, Inc on 08/31/2016
• Oritavancin - Submitted by Global Health Science on 09/30/2016

Prostate Cancer Early Detection Panel

• Genetic Risk Assessment - Submitted by Myriad on 09/21/2015
• Family History - Submitted by Myriad Genetic Laboratories, Inc. on 09/19/2016
• SelectMDx - Submitted by MDxHealth on 09/20/2016

Prostate Cancer Panel

• Sipuleucel-T - Submitted by Dendreon Corporation on 05/03/2010
• Abiraterone Acetate - Submitted by Centocor Ortho Biotech on 04/28/2011
• Sipuleucel-T - Submitted by Dendreon Corporation on 07/25/2011
• Degarelix - Submitted by Ferring Pharmaceuticals on 08/22/2011
• Degarelix - Submitted by Ferring Pharmaceuticals on 11/01/2011
• Denosumab - Submitted by Amgen on 03/30/2012
• Abiraterone Acetate - Submitted by Janssen Biotech on 12/10/2012
• Radium Ra 223 Dichloride - Submitted by Bayer Healthcare Pharmaceuticals on 05/16/2013
• Enzalutamide - Submitted by Astellas Scientific on 03/27/2014
• Molecular Assays - Submitted by Myriad on 05/16/2014
• Docetaxel in combination with androgen deprivation therapy (ADT) - Submitted by Sanofi on 06/03/2014
• Cellsearch - Submitted by Janssen Diagnostics, LLC on 04/24/2015
• ProMark - Submitted by Johns Hopkins Medical Insitutions on 05/01/2015
• Decipher® Prostate Cancer Classifier - Submitted by GenomeDx Biosciences Inc. on 05/12/2015
• Oncotype DX Prostate Cancer Assay - Submitted by Genomic Health Inc. on 05/29/2015
• Enzalutamide - Submitted by Astellas Pharma on 06/02/2015
• Enzalutamide - Submitted by Astellas Pharma on 03/01/2016
• Enzalutamide - Submitted by Astellas Pharma on 05/03/2016
• 22-marker genomic classifier (GC) tumor tissue-based molecular assay - Submitted by GenomeDx Biosciences Inc. on 05/26/2016
• Genetic risk assessment/testing - Submitted by Myriad Genetic Laboratories, Inc. on 05/27/2016
• PET/CT Imaging - Submitted by Medical Imaging & Technology Alliance on 05/27/2016
• PET Imaging - Submitted by Blue Earth Diagnostics, Inc. on 05/27/2016
• PTEN status - Submitted by Eastern Virginia Medical School on 06/09/2016
• Uridine triacetate - Submitted by Wellstat Therapeutics on 08/16/2016

Small Cell Lung Cancer Panel

• 18F-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography (FGD PET/CT) - Submitted by Medical Imaging & Technology Alliance on 03/31/2014
• Nivolumab - Submitted by Bristol-Myers Squibb Company on 06/04/2016

Smoking Cessation Panel

• Vaping/E-Cigarettes - Submitted by Robert B. Sklaroff MD on 11/23/2015
• Vaping/E-Cigarettes - Submitted by Robert B. Sklaroff MD on 07/11/2016

Soft Tissue Sarcoma Panel

• Regorafenib - Submitted by Bayer Healthcare Pharmaceuticals on 10/03/2012

Survivorship Panel

• Genetic risk assessment/testing - Submitted by Myriad Genetic Laboratories, Inc. on 10/28/2015
• Bioimpedance spectroscopy (L-Dex U400) - Submitted by ImpediMed, Inc. on 10/28/2015
• Genetic risk assessment - Submitted by Myriad Genetic Laboratories, Inc. on 10/10/2016

Thyroid Carcinoma Panel

• Sorafenib - Submitted by Bayer HealthCare Pharmaceuticals and Onxy Pharmaceuticals, Inc. on 06/26/2013
• Lenvatinib - Submitted by Eisai Inc. on 02/25/2015
• Everolimus in combination with Sorafenib - Submitted by Novartis Pharmaceuticals Corporation on 10/16/2015